Lekovic, Danijela (36659562000)Danijela (36659562000)LekovicGotic, Mirjana (7004685432)Mirjana (7004685432)GoticMilic, Natasa (7003460927)Natasa (7003460927)MilicZivojinovic, Biljana (57193694978)Biljana (57193694978)ZivojinovicJovanovic, Jelica (57202914654)Jelica (57202914654)JovanovicColovic, Natasa (6701607753)Natasa (6701607753)ColovicMilosevic, Violeta (24399200100)Violeta (24399200100)MilosevicBogdanovic, Andrija (6603686934)Andrija (6603686934)Bogdanovic2025-06-122025-06-122017https://doi.org/10.1080/10245332.2017.1302179https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015864573&doi=10.1080%2f10245332.2017.1302179&partnerID=40&md5=80c3ee4f0ec5cb7671c8e49e40d6d88fhttps://remedy.med.bg.ac.rs/handle/123456789/6794Objective: Until recently, imatinib was the standard first-line treatment in chronic myeloid leukemia (CML). The inclusion of nilotinib and dasatinib as first-line options in CML raised a debate on treatment selection. The aim of our study was to analyze predictive parameters for imatinib response as the first-line treatment of CML patients. Methods: The study included 168 consecutive patients with chronic phase Philadelphia-positive CML who were diagnosed and treated with Imatinib 400 mg once daily at a single university hospital. Numerous parameters were analyzed in terms of imatinib response including comorbidities as well as occurrence of second malignancies. Results: After the median follow-up of 87 months in 61 patients (36.3%), the imatinib failure was verified. Cox regression analysis identified hepatomegaly (p = 0.001), leukocytosis ≥ 100 × 109/l (p = 0.001), blood blasts ≥ 1% (p = 0.002), and the presence of additional cytogenetic aberrations (p = 0.002) as predictors of Imatinib failure. Based on these findings, a new prognostic model was developed according to which imatinib failure had 17% (8/47) of patients in low risk, 34.9% (30/86) of patients in intermediate risk, and 76.7% (23/30) of patients in high-risk group (HR = 3.973, 95% CI for HR 2.237–7.053, p < 0.001). Conclusion: The new score allows better selection of patients who are suitable for treatment with imatinib and may guideline the clinical decision for front-line treatment of CML. © 2017 Informa UK Limited, trading as Taylor & Francis Group.chronic myeloid leukemiaimatinibMyeloproliferative neoplasmsprediction